Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma

書誌詳細
主要な著者:	Moran, A, Ramakrishnan, S, Borg, C, Connolly, C, Couillard, S, Mwasuku, C, Pavord, I, Hinks, T, Lehtimaki, L
フォーマット:	Conference item
言語:	English
出版事項:	European Respiratory Society 2020

類似資料

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
著者:: Moran, AM, 等
出版事項: (2020)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
著者:: Shrimanker, R, 等
出版事項: (2017)

Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis
著者:: Charlene Desaintjean, 等
出版事項: (2024-03-01)

Glucocorticoids and mepolizumab in eosinophilic asthma.
著者:: Bel, E, 等
出版事項: (2014)

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
著者:: Andrea Portacci, 等
出版事項: (2023-10-01)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
著者:: Bel, E, 等
出版事項: (2014)

Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma
著者:: S. K. Zyryanov, 等
出版事項: (2020-12-01)

Mepolizumab in refractory eosinophilic asthma.
著者:: Pavord, I, 等
出版事項: (2010)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
著者:: Arian Ghassemian, 等
出版事項: (2021-01-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
著者:: Pavord, I
出版事項: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
著者:: Haldar, P, 等
出版事項: (2009)

Airway proteomics reveals broad residual anti-inflammatory effects of prednisolone in mepolizumab-treated asthma
著者:: Howell, I, 等
出版事項: (2024)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
著者:: Erminia Ridolo, 等
出版事項: (2020-10-01)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
著者:: Kayser MZ, 等
出版事項: (2021-07-01)

Mepolizumab treatment in patients with severe eosinophilic asthma.
著者:: Ortega, H, 等
出版事項: (2014)

Mepolizumab for eosinophilic COPD
著者:: Sciurba, F, 等
出版事項: (2018)

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab
著者:: Osamu Matsuno, 等
出版事項: (2019-01-01)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
著者:: Yancey, S, 等
出版事項: (2016)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
著者:: Menzella F, 等
出版事項: (2016-06-01)

Reductions in Eosinophil Biomarkers by Benralizumab in Patients With Asthma
著者:: Mirhojjat Khorasanizadeh, 等
出版事項: (2017-07-01)

Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma
著者:: Gómez-Bastero Fernández A, 等
出版事項: (2022-05-01)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
著者:: Gunsoy, N, 等
出版事項: (2017)

Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
著者:: Laura J. Walsh, 等
出版事項: (2023-01-01)

Mepolizumab asthma treatment failure due to refractory airway eosinophilia, which responded to benralizumab
著者:: Alistair Cook, 等
出版事項: (2021-05-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
著者:: Howell, I, 等
出版事項: (2024)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
著者:: Imran Howell, 等
出版事項: (2024-07-01)

Discontinuation of benralizumab in Canadian patients with severe eosinophilic asthma
著者:: Stephen G. Noorduyn, 等
出版事項: (2021-12-01)

The clinical profile of benralizumab in the management of severe eosinophilic asthma
著者:: Francesco Menzella, 等
出版事項: (2016-12-01)

Derivation of a prototype asthma attack risk scale centred on blood eosinophils and exhaled nitric oxide
著者:: Couillard, S, 等
出版事項: (2021)

Asthma in pregnancy: An update
著者:: Couillard, S, 等
出版事項: (2020)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
著者:: Shrimanker, R, 等
出版事項: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
著者:: Ortega, H, 等
出版事項: (2016)

Clinical outcomes with mepolizumab therapy in routine practice in the oxford cohort
著者:: Gittins, A, 等
出版事項: (2018)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
著者:: Steven W. Yancey, 等
出版事項: (2019-09-01)

Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab
著者:: Lisha Li, 等
出版事項: (2021-06-01)

Efficacy and safety of benralizumab in elderly patients with severe eosinophilic asthma
著者:: Kohei Somekawa, 等
出版事項: (2024-12-01)

Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial
著者:: Andrew Menzies-Gow, 等
出版事項: (2019-09-01)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
著者:: Shrimanker, R, 等
出版事項: (2018)

Utility of adherence checks in patients with severe asthma eligible for biologics: a single centre retrospective analysis
著者:: Oliver, ME, 等
出版事項: (2021)

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis
著者:: Carlos Martínez-Rivera, 等
出版事項: (2021-01-01)